Highlights Sumitomo Pharma Co., Ltd.

Equities

4506

JP3495000006

Delayed Japan Exchange Other stock markets 12:40:05 2024-06-14 am EDT			5-day change	1st Jan Change
342 ^JPY	+1.79%		+0.29%	-26.61%

May. 14	Transcript : Sumitomo Pharma Co., Ltd., 2024 Earnings Call, May 14, 2024
May. 14	Sumitomo Pharma Co., Ltd. Provides Consolidated Earnings Guidance for the Year Ending March 31, 2024	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Sumitomo Pharma Co., Ltd. Provides Consolidated Earnings Guidance for the Year Ending March 31, 2024	May. 14	CI
Sumitomo Pharma Co., Ltd. Announces No Dividend for the Year Ended March 31, 2024	May. 14	CI
Sumitomo Pharma Co., Ltd. agreed to acquire MELTz Business of MELTIN MMI Co., Ltd.	May. 08	CI
Fed Outlook, Earnings Season Roil Asian Stock Markets	May. 02	MT
Sumitomo Pharma Sees Impairment Losses and Restructuring Expenses in Fiscal 2024	May. 02	MT
Sumitomo Pharma Expects Substantial Valuation Loss on Subsidiary Shares; Assures No Impact on Consolidated Profit	May. 02	MT
Lull in Geopolitical Tensions Lifts Asian Stock Markets	Apr. 22	MT
Roivant Sciences Says Study of Potential Uveitis Treatment Meets Endpoints; Launches Stock Repurchase; Shares Rise	Apr. 02	MT
Roivant's anti-inflammatory drug succeeds in mid-stage study	Apr. 02	RE
Sumitomo Pharma Amends Collaboration Agreement with Otsuka Pharmaceutical	Mar. 17	MT
Sumitomo Pharma Enters into an Agreement to Amend the Worldwide Collaboration and License Agreement for Four Psychiatry and Neurology Compounds Including Ulotaront with Otsuka	Mar. 15	CI
Otsuka Holdings' Attributable Profit Down 9.2% 2023 On Impairment Losses	Feb. 16	MT
Sumitomo Pharma Co., Ltd. Provides Dividend Guidance for the Fiscal Year Ending March 31, 2024	Jan. 31	CI
Sumitomo Pharma Co., Ltd. Revises Consolidated Earnings Guidance for the Year Ending March 31, 2024	Jan. 31	CI
Gedeon Richter Plc., Sumitomo Pharma America, Inc. and Sumitomo Pharma Switzerland, GmbH Receives European Commission grant for Commercialisation of RYEQO®	Nov. 02	CI
Sumitomo Pharma Co., Ltd. Reports Earnings Results for the Half Year Ended September 30, 2023	23-10-31	CI
Sumitomo Pharma Co., Ltd. Provides Dividend Guidance for the Second Quarter and Full Year of Fiscal Year Ending March 31, 2024	23-10-31	CI
Sumitomo Pharma Announces Positive Topline Results from Phase 3 Clinical Studies Evaluating Vibegron in Men with Overactive Bladder Symptoms Receiving Pharmacological Therapy for Benign Prostatic Hyperplasia	23-09-11	CI
Sumitomo Pharma Co., Ltd. Provides Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2024	23-07-31	CI
Sumitomo Pharma Co., Ltd. Provides Dividend Guidance for the Second Quarter and Full Year of Fiscal Year Ending March 31, 2024	23-07-31	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Sumitomo Pharma Co., Ltd.

Equities

4506

JP3495000006

Highlights

Filters